

Drugs@FDA: FDA-Approved Drugs

 [SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020121\)](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020121)

 [TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA-APPROVED DRUGS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020121\)](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA-Approved Drugs&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020121)

 [LINKEDIN \(HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020121&TITLE=DRUGS@FDA: FDA-APPROVED DRUGS&SOURCE=FDA\)](https://www.linkedin.com/sharearticle?mini=true&url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020121&title=Drugs@FDA: FDA-Approved Drugs&source=fda)

 [PIN IT \(HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON/?URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020121&DESCRIPTION=DRUGS@FDA: FDA-APPROVED DRUGS\)](https://www.pinterest.com/pin/create/button/?url=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020121&description=Drugs@FDA: FDA-Approved Drugs)



 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA-APPROVED DRUGS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=020121\)](mailto:?subject=Drugs@FDA: FDA-Approved Drugs&body=https://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process&applno=020121)

 PRINT

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 020121

Company: GLAXOSMITHKLINE

 [EMAIL \(MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=020121\)](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daif/index.cfm?event=overview.process%26varapplno=020121)

[Products on NDA 020121](#)



[CSV](#)
[Excel](#)
[Print](#)

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
FLONASE	FLUTICASONE PROPIONATE	0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	SPRAY, METERED;NASAL	Discontinued	None	Yes	No

Showing 1 to 1 of 1 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 020121



Original Approvals or Tentative Approvals

[CSV](#)
[Excel](#)
[Print](#)

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes
10/19/1994	ORIG-1	Approval	Type 3 - New Dosage Form	STANDARD		Label is not available on this site.

Showing 1 to 1 of 1 entries

Supplements

[CSV](#)
[Excel](#)
[Print](#)

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
01/07/2019	SUPPL-45	Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/020121Orig1s045ltr.pdf)
01/23/2015	SUPPL-44	Labeling- Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020121s044lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/020121Orig1s044ltr.pdf)
06/17/2014	SUPPL-43	Manufacturing (CMC)	
06/17/2014	SUPPL-42	Manufacturing (CMC)	
06/19/2013	SUPPL-41	Manufacturing (CMC)	
03/26/2004	SUPPL-30	Labeling	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20549s1r016,20548s1r020,20121s1r030_flonid) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20549s1r016,20548s1r020,20121s1r030ltr)

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
05/01/2003	SUPPL-28	Efficacy-Labeling Change With Clinical Data	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020121s028lbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/20121se8-028ltr.pdf)
05/23/2002	SUPPL-23	Efficacy-New Dosing Regimen	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20121s023ltr.pdf)
05/09/2002	SUPPL-20	Labeling	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/NDA20121S011.pdf)
05/09/2002	SUPPL-13	Labeling	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/NDA20121S011.pdf)
05/09/2002	SUPPL-11	Labeling	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/NDA20121S011.pdf)

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
05/07/2002	SUPPL-26	Manufacturing (CMC)-Packaging	
03/04/2002	SUPPL-25	Manufacturing (CMC)-Control	
02/19/2002	SUPPL-24	Manufacturing (CMC)-Control	
08/03/2001	SUPPL-17	Manufacturing (CMC)-Control	
07/09/2001	SUPPL-22	Manufacturing (CMC)-Control	

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
06/25/2001	SUPPL-21	Manufacturing (CMC)-Control	
09/26/2000	SUPPL-8	Manufacturing (CMC)-Control	
06/20/2000	SUPPL-16	Manufacturing (CMC)	
05/17/2000	SUPPL-15	Manufacturing (CMC)-Control	
02/18/2000	SUPPL-12	Manufacturing (CMC)	

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
12/11/1998	SUPPL-9	Efficacy-New Indication	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20121-S009_FLONASE_prntlbl.pdf) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20121s9ltr.pdf) Review (https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20121S009_Flonase.cfm)
10/01/1998	SUPPL-10	Labeling	
02/18/1998	SUPPL-6	Manufacturing (CMC)-Control	
10/31/1997	SUPPL-5	Efficacy-New Indication	Review (PDF) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20121.pdf)
12/12/1996	SUPPL-4	Labeling	

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert
03/27/1996	SUPPL-3	Labeling	
08/01/1995	SUPPL-2	Manufacturing (CMC)-Control	

Showing 1 to 28 of 28 entries

Labels for NDA 020121

